Akebia Therapeutics (AKBA) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 170.6% versus a loss of 71.4%. Over five years, AKBA leads with a -71.4% price change compared with -92.8% for QTTB. Q32 Bio is the larger company by market cap ($240.8 million vs $225.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | QTTB |
|---|---|---|
| Share price | $0.8148 | $8.09 |
| Market cap | $225.79M | $240.83M |
| 1-day change | -6.71% | +1.25% |
| YTD return | -49.39% | +143.67% |
| 1-year return | -71.41% | +170.57% |
| 5-year return | -71.41% | -92.75% |
| P/E ratio (TTM) | — | 2.57 |
| EPS (TTM) | $-0.12 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $23.57 |
| 52-week low | $0.814 | $1.91 |
| Distance from 52-week high | -74.54% | -65.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +381.10% | +389.49% |
| Average volume | 6.18M | 1.38M |
| Shares outstanding | 277.11M | 29.77M |
| Employees | 194 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed AKBA by 242.0 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
AKBA vs QTTB FAQ
Which is bigger, Akebia Therapeutics or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $240.83M compared with $225.79M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or QTTB?
QTTB returned +170.57% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.